Delisting risk
Ensysce Biosciences
Develops opioid-safety prodrugs and a neuroplastogenic pain candidate.
$0.3999
Pre-market+0.01 (+1.86%)
At close$0.3926(−1.83%)
Something off on this page? Send us feedback.
Next report
Nov 13, 2026
estimated · in 73 days
EPS estimate
−$0.19
Revenue estimate
$1.2M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$1.39−$0.79−$1.29−$0.75−$0.52−$0.20−$0.20Pending
Estimate−$3.02−$1.02−$0.85−$1.26−$0.73−$0.50−$0.20−$0.19
Surprise+54.0%+22.5%−51.8%+40.5%+28.8%+60.0%0.0%—
RevenueReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported$1.3M$1.4M$493.1K$1.9M$961.0K—$1.2MPending
Estimate—$1.4M$700.0K$503.0K$1.0M$1.9M$1.2M$1.2M
Surprise—−2.0%−29.6%+277.8%−3.9%—−3.0%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.19 | — | — |
| Aug 2026 | −$0.20 | −$0.20 | 0.0% |
| Aug 2026 | −$0.50 | −$0.20 | +60.0% |
| May 2026 | −$0.73 | −$0.52 | +28.8% |
| Mar 2026 | −$1.26 | −$0.75 | +40.5% |
The latest year is open to everyone — the 33 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Jan 2018 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | −$0.19 | — | — | $1.2M | — | — | — |
| Aug 13, 2026 | −$0.20 | −$0.20 | 0.0% | $1.2M | $1.2M | −3.0% | −12.6% |
| Aug 12, 2026 | −$0.50 | −$0.20 | +60.0% | $1.9M | — | — | −12.6% |
| May 15, 2026 | −$0.73 | −$0.52 | +28.8% | $1.0M | $961.0K | −3.9% | +13.2% |
| Mar 30, 2026 | −$1.26 | −$0.75 | +40.5% | $503.0K | $1.9M | +277.8% | +4.8% |
The latest year is open to everyone — the 33 quarters behind it read with an account. Sign in | |||||||
| Nov 14, 2025 | |||||||
| Aug 13, 2025 | |||||||
| May 13, 2025 | |||||||
| Mar 10, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 14, 2024 | |||||||
| May 10, 2024 | |||||||
| Mar 15, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 11, 2023 | |||||||
| May 15, 2023 | |||||||
| Mar 30, 2023 | |||||||
| Nov 14, 2022 | |||||||
| Aug 11, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 31, 2022 | |||||||
| Nov 15, 2021 | |||||||
| Aug 16, 2021 | |||||||
| Jun 8, 2021 | |||||||
| Mar 15, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Aug 7, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 10, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 7, 2019 | |||||||
| May 7, 2019 | |||||||
| Mar 11, 2019 | |||||||
| Nov 7, 2018 | |||||||
| Aug 1, 2018 | |||||||
| May 3, 2018 | |||||||
| Mar 9, 2018 | |||||||
| Jan 9, 2018 | |||||||